Correction: AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma

J Exp Clin Cancer Res. 2023 Apr 19;42(1):91. doi: 10.1186/s13046-023-02672-7.

¹ Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, Nanjing, 210023, China.
² School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
³ School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
⁴ School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China. [email protected].
⁵ School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China. [email protected].
⁶ School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China. [email protected].
⁷ State Administration of Traditional Chinese Medicine Key Laboratory of Chinese Medicinal Resources Recycling Utilization, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing, 210023, China. [email protected].
⁸ School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China. [email protected].

^# Contributed equally.

No abstract available

Publication types